
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using Read More
BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to Read More